The Globe and Mail reports in its Friday edition that National Bank Financial analyst Maxim Sytchev has reaffirmed his "outperform" recommendation and $65 share target for ATS. The Globe's David Leeder writes that analysts on average target the shares at $66. Mr. Sytchev believes ATS shares are "oversold and fundamentally deserve to go to prior highs." He calls ATS's third quarter a "good performance" and sees a bullish outlook "anchored in secularly positioned reality." Mr. Sytchev says in a note: "As with many other industrials, investors have been increasingly worried that the pace of growth we've seen over the last 12 to 15 months is an aberration and we are cycling back to much lower momentum. While we certainly don't expect the repeat of 16-per-cent organic growth any time soon, we believe the outlook/margin is good enough to establish a floor for the stock at this level (admittedly, shares sold off almost 20 per cent since the U.S. listing). ... We believe shares are attractively valued for an entity with a much more secular growth profile vs. its own history, product-ization of the revenue shift, upside to margin profile over time to the 15-per-cent EBIT target and strong positioning with healthcare."